Last $1.99 USD
Change Today -0.0136 / -0.68%
Volume 132.7K
CBMX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

combimatrix corp (CBMX) Snapshot

Open
$2.01
Previous Close
$2.00
Day High
$2.05
Day Low
$1.95
52 Week High
03/19/14 - $3.65
52 Week Low
10/6/14 - $1.09
Market Cap
25.2M
Average Volume 10 Days
187.1K
EPS TTM
$-0.58
Shares Outstanding
12.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COMBIMATRIX CORP (CBMX)

Related News

No related news articles were found.

combimatrix corp (CBMX) Related Businessweek News

No Related Businessweek News Found

combimatrix corp (CBMX) Details

CombiMatrix Corporation provides molecular diagnostic solutions and clinical support services. It focuses on miscarriage analysis, prenatal testing, and pediatric genetics, as well as offers DNA-based testing for the detection of genetic abnormalities. The company develops and markets molecular testing services for prenatal/postnatal developmental disorders and hematology/oncology genomics. Its developmental disorder suite of array tests focus on the prenatal and postnatal application of microarrays in diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features, and autism spectrum disorders. The company’s oncology diagnostic tests include a series of diagnostic microarray tests that provide additional genomic information to physicians through the genetic analysis of blood, tissue, or biopsy samples. The microarray testing addresses various common hematological malignancies primarily chronic lymphocytic leukemia. The company serves commercial insurance companies, healthcare institutions, government payors, and individuals. CombiMatrix Corporation was founded in 1995 and is headquartered in Irvine, California.

combimatrix corp (CBMX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $287.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $262.0K
Compensation as of Fiscal Year 2013.

combimatrix corp (CBMX) Key Developments

CombiMatrix Corporation Reports Audited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

CombiMatrix Corporation reported audited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $2.2 million, a 26.5% increase over total revenues of $1.8 million for the fourth quarter of 2013. The increase in Revenue was driven primarily by increased volumes of both microarray and non-microarray diagnostic tests despite a reduction in oncology volumes and revenues as the Company exited that business during 2014. Net loss attributable to common stockholders was $1.6 million against $7.7 million a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.15 against $1.44 a year ago. The net loss in the fourth quarter of 2014 was negatively impacted primarily by increased sales and marketing costs as well as from certain warrant derivative gains recognized during the fourth quarter of 2013 that did not repeat during the fourth quarter of 2014. Operating loss was $1.6 million against $1.4 million last year. For the fourth quarter and year ended December 31, 2014, net cash used in operating activities was $2.0 million and $8.6 million, respectively, compared to $1.5 million and $5.6 million in the comparable 2013 periods, respectively. The increase in net cash used in operating activities for all periods presented was due primarily to increased cash spent on ongoing litigation. Total revenues for the year increased to $8.0 million from $6.4 million last year. Operating loss was $8.7 million against $6.4 million last year. Net loss attributable to common stockholders was $8.7 million against $3.9 million a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.79 against $3.11 a year ago. The increase in Revenue was also driven primarily by increased volumes of microarray diagnostic tests year-over-year, despite decreased oncology volumes and revenues as the company exited that business during 2014.

CombiMatrix Announces Payor Contract with Fortified Provider Network

CombiMatrix Corporation announced it has entered into a contractual agreement with Fortified Provider Network ("FPN") for coverage of CombiMatrix's suite of diagnostic laboratory services. FPN has over 200 payor clients nationwide and contracts with physicians, hospitals, ancillary facilities, mid-level providers and other specialty healthcare providers who have the option of participating in one or more of their products (group health, workers compensation or auto liability).

CombiMatrix Corporation to Report Q4, 2014 Results on Feb 25, 2015

CombiMatrix Corporation announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 25, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBMX:US $1.99 USD 0.00

CBMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBMX.
View Industry Companies
 

Industry Analysis

CBMX

Industry Average

Valuation CBMX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COMBIMATRIX CORP, please visit www.combimatrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.